Lineage Cell Therapeutics
LCTX
LCTX
114 hedge funds and large institutions have $85.6M invested in Lineage Cell Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 7 closing their positions.
Holders
114
Holders Change
+1
Holders Change %
+0.88%
% of All Funds
1.65%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
30
Reduced
24
Closed
7
Calls
$58K
Puts
$1K
Net Calls
+$57K
Net Calls Change
-$43K
Top Buyers
1 |
1
BlackRock
New York
|
$8.98M |
2 |
2
Morgan Stanley
New York
|
$768K |
3 |
LGM
3
Logos Global Management
San Francisco,
California
|
$4.53M |
4 |
4
Barclays
London,
United Kingdom
|
$192K |
5 |
RA
5
Raffles Associates
New York
|
$4.08M |